巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Inozyme Pharma

    INZY
    3.980
    0.010
    0.25%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Inozyme Pharma - 延遲價格・最後更新於 26/05 4:15
    最高位
    4.020
    最低位
    3.820
    開市價
    --
    前收市價
    3.990
    成交量(千)
    3.12
    成交額(百萬)
    0.11
    買入
    3.960
    賣出
    4.020
    每手股數
    --
    市值(百萬)
    159.59
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    19.580 - 3.540
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Inozyme Pharma
    證券代碼
    INZY.US
    所屬板塊
    Biotechnology
    公司業務
    Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
    發行量
    23672566
    公司總部
    321 Summer Street, Suite 400
    公司網址
    https://www.inozyme.com
    公司電郵
    axel.bolte@inozyme.com
    公司電話
    +1 857 330-4340
    暫無內容

    關於

    Inozyme Pharma(INZY.US)所屬的行業板塊為Biotechnology。
    Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
    詳細公司背景可參考: https://www.inozyme.com